APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Conditions:   Pancreatic Acinar Cell Carcinoma;   Pancreatic Adenosquamous Carcinoma;   Pancreatic Squamous Cell Carcinoma;   Resectable Pancreatic Acinar Cell Carcinoma;   Resectable Pancreatic Adenocarcinoma;   Resectable Pancreatic Adenosquamous Carcinoma;   Resectable Pancreatic Carcinoma
Interventions:   Drug: Olaparib;   Drug: Placebo Administration
Sponsor:   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 7, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments